This page shows what was measured, who it was measured in, and what that does not settle.
What Elinzanetant does in the body
Moderate to severe vasomotor symptoms (VMS) due to menopause
From the FDA-approved label: LYNKUET is a neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist. Inhibition of Substance P and Neurokinin B through antagonism of NK1 and NK3 receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons can modulate neuronal activity in thermoregulation associated with hot flashes. 0).
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · NZW2BOW35N · read 2026-08-29
Its recorded molecular formula is C33H35F7N4O3, weighing 668.7.
US prescribing information · f42884ff-7dff-419c-8a0c-affe2ed73818 · read 2026-08-30
Where each sentence above came from
The recorded explanation is written in label language rather than for a beginner. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 71 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD])
✗ The study did not show it
Who was studied
NCT05030584
How many people
628
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Mean Change in Frequency of Moderate to Severe Hot Flashes (HF) From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD])
✗ The study did not show it
Who was studied
NCT05587296
How many people
474
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)
✗ The study did not show it
Who was studied
NCT05099159
How many people
400
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD]).
✗ The study did not show it
Who was studied
NCT05042362
How many people
396
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 4
✗ The study did not show it
Who was studied
NCT03596762
How many people
199
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Change From Baseline in Wakefulness After Sleep Onset (WASO) at Week 4 as Measured by Polysomnography (PSG)
✗ The study did not show it
Who was studied
NCT06112756
How many people
110
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
□Living longer, or avoiding a major eventNo evidence recorded. Death, a heart attack, a stroke, a hospital stay.No registered study measures this.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.1 registered measure of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
□AnimalsNo evidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.No animal record is stored.
□Cells in a dishNo evidence recorded. Cells or chemistry on a bench, far from a whole body.No cell or bench record is stored.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
maximum observed drug concentration
Meaningful
Things that change how a life goes, not only a number.
No registered study measured anything of this kind.
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (4)
frequency of moderate to severe hf from baseline to week 4
frequency of moderate to severe hf from baseline to week 12
severity of moderate to severe hf from baseline to week 4
severity of moderate to severe hf from baseline to week 12
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 45 hours hours
Read from the label, which states: “Elimination Elinzanetant elimination half-life was approximately 45 hours in women with vasomotor symptoms.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
LYNKUET is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. LYNKUET is a neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. ( 1 )
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The efficacy and safety of LYNKUET in pediatric patients have not been established, and LYNKUET is not indicated in this population.”
US prescribing information · f42884ff-7dff-419c-8a0c-affe2ed73818 · read 2026-08-30
On older people, the label states: “There have not been sufficient numbers of geriatric women involved in clinical trials utilizing LYNKUET to determine whether those over 65 years of age differ from younger women in their response to LYNKUET.”
US prescribing information · f42884ff-7dff-419c-8a0c-affe2ed73818 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary LYNKUET is contraindicated in pregnancy [see Contraindications (4) ].”
US prescribing information · f42884ff-7dff-419c-8a0c-affe2ed73818 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There are no data on the presence of elinzanetant or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production.”
US prescribing information · f42884ff-7dff-419c-8a0c-affe2ed73818 · read 2026-08-30
On people with reduced liver function, the label states: “No dose adjustment is required in patients with mild (Child-Pugh A) hepatic impairment.”
US prescribing information · f42884ff-7dff-419c-8a0c-affe2ed73818 · read 2026-08-30
On people with reduced kidney function, the label states: “No dose adjustment is required for patients with mild to severe [estimated glomerular filtration rate (eGFR) 15 to < 90 mL/min] renal impairment.”
US prescribing information · f42884ff-7dff-419c-8a0c-affe2ed73818 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
Sold as capsule, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
1 product lists this as an active ingredient in the United States drug directory. 1 of them contain it and nothing else.
FDA National Drug Code directory · 50419-475 · read 2026-08-29
They are sold as capsule, taken oral.
FDA National Drug Code directory · 50419-475 · read 2026-08-29
1 published label names it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · f42884ff-7dff-419c-8a0c-affe2ed73818 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · f42884ff-7dff-419c-8a0c-affe2ed73818 · read 2026-08-29
LYNKUET is oral at 3 DOSAGE FORMS AND STRENGTHS Capsules: 60 mg, opaque red, oblong, soft, gelatin capsules, with white printing of "EZN60"., recorded as fda label in effect 2026-06-16 in the United States.
US prescribing information · f42884ff-7dff-419c-8a0c-affe2ed73818 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.
Questions worth asking
Which of the trials of Elinzanetant studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Elinzanetant are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
FDA substance identifier (UNII)
NZW2BOW35N
RxNorm concept
2725516
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✗ Not passed
Safety mode resolved
No register row and no identity class settled the question.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
1 approved application covers products containing this substance. The earliest was NDA219469, approved 20251024 to BAYER HLTHCARE.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (11)
Q1
What did Elinzanetant's largest trial (628 people) and its longest (5.6 years) measure?
628 people in Elinzanetant's largest registered study, 5.6 years in its longest registered window, measuring Maximum Observed Plasma Concentration (Cmax) of BAY3427080. ClinicalTrials.gov · 2026-09-01
12 phase1, 4 phase2, 4 phase3; NCT05587296; 2028-06-05; no ageing endpoint recorded. Last human test completed 2024, NCT06112756.
Interpretation These counts include studies where Elinzanetant was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase1
12
phase2
4
phase3
4
Last recorded human testNCT06112756
2024-11-07
recorded 2026-09-01 · last checked 2026-09-04
Q2
Elinzanetant was tested only in human — what did it show?
3 recorded entries; human; also "NT-814 100 mg", "NT-814 200 mg"
Show the evidence
human
NCT02692157
NT-814 50 mg
NCT02692157
NT-814 100 mg
NCT02692157
NT-814 200 mg
recorded 2026-09-01 · last checked 2026-09-04
Q5
Elinzanetant's half-life is 45 hours — which schedules were studied?
45 hours, the half-life Elinzanetant's label states. openfda-label · f42884ff-7dff-419c-8a0c-affe2ed73818 · 2026-08-30
bioavailability 52% %.
Show the evidence
half life
45 hours hours; Elimination Elinzanetant elimination half-life was approximately 45 hours in women with vasomotor symptoms.
tmax
Absorption Elinzanetant median (min-max) time to maximum plasma concentration (T max ) is 1.0 hours (1-2.5 hours) at steady state.
bioavailability
52% %; Elinzanetant absolute bioavailability is 52% following oral administration.
metabolism
Metabolism Elinzanetant is primarily metabolized by CYP3A4 to yield three major active metabolites, M18/21, M27, and M30/34.
recorded 2026-08-30 · last checked 2026-09-04
Q6
Could one person measure Elinzanetant's effect on frequency of moderate to severe hf from baseline to week 4?
Frequency of moderate to severe hf from baseline to week 4: measured in Elinzanetant's trials.
frequency of moderate to severe hf from baseline to week 4 is the recorded endpoint.
Show the evidence
biomarkers
frequency of moderate to severe hf from baseline to week 4; 2026-09-01
frequency of moderate to severe hf from baseline to week 12; 2026-09-01
severity of moderate to severe hf from baseline to week 4; 2026-09-01
severity of moderate to severe hf from baseline to week 12; 2026-09-01
maximum observed drug concentration; 2026-09-01
half life
2026-09-04; halfLife; hours; 45 hours; 2026-08-30
human trials at or under30
7
smallest human trial
0; NCT02692157; PHASE1/PHASE2; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; WITHDRAWN
Q7
Which of frequency of moderate to severe hf from baseline to week 12, frequency of moderate to severe hf from baseline to week 4 and maximum observed drug concentration did Elinzanetant's trials measure?
frequency of moderate to severe hf from baseline to week 12, frequency of moderate to severe hf from baseline to week 4 and maximum observed drug concentration lead 5 outcome terms across Elinzanetant's trials. ClinicalTrials.gov · 2026-09-01
severity of moderate to severe hf from baseline to week 12 and maximum observed drug concentration follow.
Show the evidence
frequency of moderate to severe hf from baseline to week 4
1
frequency of moderate to severe hf from baseline to week 12
1
severity of moderate to severe hf from baseline to week 4
1
severity of moderate to severe hf from baseline to week 12
1
maximum observed drug concentration
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
What will the one ongoing trial of Elinzanetant report, and when?
Mean Change in Frequency of Moderate to Severe Hot Flashes (HF) From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD])
Show the evidence
TrialNCT05587296
"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer"; n 474; "Mean Change in Frequency of Moderate to Severe Hot Flashes (HF) From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD])"; 2028-06-05
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which 10 trials of Elinzanetant posted no result?
Posted no result
10 of 10 completed trials
Registrations
NCT04889287, NCT05028608, NCT05061563, NCT04981431, NCT05351892 and NCT05381142, and 4 more
Completion dates
oldest 2021-09-29; newest 2024-04-15
Show the evidence
Trial
NCT04889287
2021-09-29
NCT05028608
2022-01-20
NCT05061563
2022-02-23
NCT04981431
2022-03-13
NCT05351892
2022-06-20
NCT05381142
2022-07-11
4 further recorded trials
NCT05071729
2022-10-19
NCT05471817
2022-11-14
NCT05481528
2023-04-28
NCT06219902
2024-04-15
Q10
At the median, Elinzanetant's trials enrolled 56.5 people — anything larger?
Median enrolment
56.5
Largest enrolment
628
Registered trials counted
18
Q11
Elinzanetant and CYP3A4, P-GP and BCRP: shared by which compounds?
CYP3A4, P-GP and BCRP appear in Elinzanetant's recorded interaction sentences, 13 in all. openfda-label+europepmc · 2026-08-30
In Vitro Studies Cytochrome P450 (CYP450) Enzymes: Elinzanetant and its metabolites M18/21, M27, and M30/M34 inhibited CYP3A4 but did not inhibit CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 2J2, or induce CYP1A2, 2B6, 2C19, or 3A4 at clinically relevant concentrations.
CYP1A2pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP450) Enzymes: Elinzanetant and its metabolites M18/21, M27, and M30/M34 inhibited CYP3A4 but did not inhibit CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 2J2, or induce CYP1A2, 2B6, 2C19, or 3A4 at clinically relevant concentrations.
CYP2D6pharmacokinetics
No clinically significant differences in the pharmacokinetics of the following oral drugs were observed when used concomitantly with elinzanetant: tamoxifen (substrate of CYP2D6, CYP3A4 and P-gp) and rosuvastatin (substrate of BCRP, OATP1B1/OATP1B3, and OAT3).
CYP3A4
pharmacokinetics
Metabolism Elinzanetant is primarily metabolized by CYP3A4 to yield three major active metabolites, M18/21, M27, and M30/34.
pharmacokinetics
No clinically significant differences in the pharmacokinetics of the following oral drugs were observed when used concomitantly with elinzanetant: tamoxifen (substrate of CYP2D6, CYP3A4 and P-gp) and rosuvastatin (substrate of BCRP, OATP1B1/OATP1B3, and OAT3).
pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP450) Enzymes: Elinzanetant and its metabolites M18/21, M27, and M30/M34 inhibited CYP3A4 but did not inhibit CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 2J2, or induce CYP1A2, 2B6, 2C19, or 3A4 at clinically relevant concentrations.
pharmacokinetics
Moderate to Strong CYP3A4 Inducers: Elinzanetant C max reduced by 44% and AUC reduced by 64% following concomitant use with carbamazepine (moderate to strong CYP3A4 inducer) 600 mg administered twice daily.
pharmacokinetics
Strong CYP3A4 and P-gp inhibitors: Elinzanetant C max increased approximately 3.3-fold and AUC increased 6.3-fold following concomitant use with itraconazole 200 mg (strong CYP3A4 and P-gp inhibitor).
pharmacokinetics
Moderate CYP3A4 Inhibitors: Elinzanetant C max and AUC are predicted to increase 2.0-fold and 3.0-fold, respectively, following concomitant use of elinzanetant 120 mg with erythromycin (moderate CYP3A4 inhibitor).
4 more recorded rows
CYP3A4pharmacokinetics
Weak CYP3A4 Inhibitors: Elinzanetant C max is predicted to increase 1.3-fold and AUC increase 1.5-fold following concomitant use with cimetidine (weak CYP3A4 inhibitor).
CYP3A4pharmacokinetics
PBPK predictions after co-administration of 60 mg elinzanetant [ ( see Dosage and Administration (2.3) ] with the moderate CYP3A4 inhibitor erythromycin showed a 1.4-fold increase of elinzanetant AUC and no increase for C max when compared to 120 mg, the regular recommended elinzanetant dosage.
CYP3A4clinical_pharmacology
However, QTc prolongation effect of elinzanetant when co-administered with strong CYP3A4 inhibitors has not been sufficiently characterized. 12.3 Pharmacokinetics Elinzanetant C max and AUC increased in a greater than dose-proportional manner (20% to 50%) over the dose range from 40 to 160 mg once daily (0.33 to 1.33 times the highest recommended dose).
CYP3A4pharmacokinetics
Sensitive CYP3A4 Substrates: Elinzanetant increased midazolam (sensitive CYP3A4 substrate) C max 1.5-fold and AUC 1.8-fold.
recorded 2026-08-30 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 7 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.